Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Ewing's sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11;22) (q24;q12) chromosome translocation, the breakpoints of which have recently been cloned. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ewing’s sarcoma, a common pediatric cancer, is invariably associated with ETS gene translocations (182) that result in a fusion oncogene consisting of the 5′ end of EWS and the 3′ end of FLI1, or less frequently ERG, ETV1, ETV4, or FEV (Figure 1a) (183, 184).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [183]
Citations
Cites
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,114
RNA recognition: towards identifying determinants of specificity
Kenan, D. J., Query, C. C., & Keene, J. D. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90088-d · Cited by 730
RNA-binding proteins as developmental regulators.
Bandziulis, R. J., Swanson, M. S., & Dreyfuss, G. (1989) · Genes & Development · doi:10.1101/gad.3.4.431 · Cited by 644
Turc-Carel, C., Aurias, A., Mugneret, F., Lizard, S., Sidaner, I., Volk, C., Thiery, J. P., Olschwang, S., Philip, I., Berger, M. P., et al. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90285-3 · Cited by 466
Self-citationBen-David, Y., Giddens, E. B., Letwin, K., & Bernstein, A. (1991) · Genes & Development · doi:10.1101/gad.5.6.908 · Cited by 403
Chromosome Translocation in Peripheral Neuroepithelioma
Whang-Peng, J., Triche, T. J., Knutsen, T., Miser, J., Douglass, E. C., & Israel, M. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408303110907 · Cited by 399
Chromosomal Translocations in Ewing's Sarcoma
(1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090817 · Cited by 330
Corden, J. L. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90236-5 · Cited by 327
Turc-Carel, C., Philip, I., Berger, M.-P., Philip, T., & Lenoir, G. M. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90002-5 · Cited by 291
Research works printed but not linked: 8
- Aurias, A., Rimbaut, C., Buffe, C., Dubousset, J. & Mazabraud, A. N. Engl. J. Med. 309, 496–497 (1983).
- Turc-Carel, C., Philip, I., Berge, R. M. P., Philip, T. & Lenoir, G. M. N. Engl. J. Med. 309, 497–498 (1983).
- De Chadarevian, J. P., Vekemans, M. & Seemayer, T. A. N. Engl. J. Med. 311, 1702–1703 (1984).
- Cavazzana, A. O. et al. Adv. Neuroblastoma Res. 2, 463–473 (1988).
- Zucman, J. et al. Genes Chrom. Cancer (in the press).
- Douglass, E. C., Valentine, M., Green, A. A., Hayes, F. A. & Thompson, E. I. J. natn. Cancer Inst. 77, 1211–1213 (1986).
- Watson, D. K., Ascione, R. & Papas, T. S. Crit. Rev. Oncogenesis 1, 409–436 (1990).
- Rouleau, G. A. et al. Am. J. hum. Genet. 46, 323–328 (1990).
Cited by
Items 501–600 of 1,002
DNA Methylation–Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas
Wu, S. P., Cooper, B. T., Bu, F., Bowman, C. J., Killian, J. K., Serrano, J., Wang, S., Jackson, T. M., Gorovets, D. J., Shukla, N. N., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00031 · Cited by 68
“The discovery of the EWSR1-FLI1 fusion detected by fluorescent in situ hybridization (FISH) has significantly improved diagnostic accuracy, but is only present in approximately 85% of samples that are histologically consistent with EWS [6].”
Immanuel, D., Zinszner, H., & Ron, D. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.8.4562 · Cited by 69
“An ORF present at one end of the clone encodes a protein with considerable (.50%) identity to the C-terminal RRM-containing portion of TLS and EWS (6, 7 ). The EWS-TLS homology region of the Dpen p19 cDNA (a kind gift of Susan Haynes) was used as a probe to isolate cDNA clones containing the full-length coding region.”
BackgroundMethodKedra, D. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.5.625 · Cited by 58
Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis
Stoll, G., Surdez, D., Tirode, F., Laud, K., Barillot, E., Zinovyev, A. Y., & Delattre, O. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt678 · Cited by 59
“This leads to the expression of EWS-FLI1 chimeric transcription factor (1).”
BackgroundSelf-citationSankar, S., Tanner, J. M., Bell, R. N., Chaturvedi, A. P., Randall, R. L., Beckerle, M. C., & Lessnick, S. L. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00241-13 · Cited by 59
“The vast majority of these tumors are characterized by a t(11; 22)(q24;q12) chromosomal translocation, which generates a fusion oncogene, EWS/FLI (2).”
BackgroundGeneration of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines
Oyama, R., Takahashi, M., Yoshida, A., Sakumoto, M., Takai, Y., Kito, F., Shiozawa, K., Qiao, Z., Arai, Y., Shibata, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04967-0 · Cited by 61
Profile of Ets gene expression in human breast carcinoma
He, J., Pan, Y., Hu, J., Albarracin, C. T., Wu, Y., & Dai, J. L. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.1.3551 · Cited by 65
Peripheral primitive neuroectodermal tumour of the cervix
Pauwels, P., Ambros, P. F., Hattinger, C. M., Lammens, M. M. Y., Cin, P. D., Ribot, J. G., Struyk, A. P. H. B., & BERGHE, H. V. D. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/pl00008201 · Cited by 57
“PNET is genetically characterised by different rearrangements involving the EWS gene band 22q12 [ 11 , 38, 40, 41].”
BackgroundBarr, F. G., Xiong, Q. B., & Kelly, K. M. (1995) · American Journal of Clinical Pathology · doi:10.1093/ajcp/104.6.627 · Cited by 57
Regulation of FAS Exon Definition and Apoptosis by the Ewing Sarcoma Protein
Paronetto, M. P., Bernardis, I., Volpe, E., Bechara, E., Sebestyén, E., Eyras, E., & Valcárcel, J. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.077 · Cited by 61
“For example, a translocation creating a fusion between EWS and the ETS transcription factor FLI-1 is frequent in cases of Ewing sarcoma (Delattre et al., 1992; Ross et al., 2013).”
BackgroundMethodManagement of Ewing sarcoma family of tumors: Current scenario and unmet need
Biswas, B., & Bakhshi, S. (2016) · World Journal of Orthopedics · doi:10.5312/wjo.v7.i9.527 · Cited by 62
SPOP and OTUD7A Control EWS–FLI1 Protein Stability to Govern Ewing Sarcoma Growth
Su, S., Chen, J., Jiang, Y., Wang, Y., Vital, T., Zhang, J., Laggner, C., Nguyen, K. T., Zhu, Z., Prevatte, A. W., et al. (2021) · Advanced Science · doi:10.1002/advs.202004846 · Cited by 70
Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein
Spahn, L., Siligan, C., Bachmaier, R., Schmid, J. A., Aryee, D. N. T., & Kovar, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206810 · Cited by 61
“The protein is encoded by the fusion gene EWS-FLI1, which results from the chromosomal translocation t(11;22)(q24;q12) (Delattre et al., 1992).”
BackgroundSelf-citationDominant negative PDGF-C inhibits growth of Ewing family tumor cell lines
Zwerner, J. P., & May, W. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205486 · Cited by 59
“EFT are united by their extremely high association with aberrant transcription factors fusing the amino terminal portion of the EWS gene with the carboxyl terminus of a member of the ETS transcription factor family (Delattre et al., 1992).”
BackgroundLerman, D. M., Monument, M. J., McIlvaine, E. J., Liu, X., Huang, D., Monovich, L., Beeler, N., Gorlick, R. G., Marina, N. M., Womer, R. B., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25340 · Cited by 60
Caveolin-1 Modulates the Ability of Ewing's Sarcoma to Metastasize
Sáinz‐Jaspeado, M., Lagares‐Tena, L., Lasheras, J., Navid, F., Galindo, C. R., Mateo‐Lozano, S., Notario, V., Sanjuán, X., del Muro, X. G., Fabra, À., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0060 · Cited by 65
“EWS/FLI-1 protein levels were unaffected by downregulation of CAV1 (Supplementary Fig.”
BackgroundInfluentialTargeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma
Guan, H., Zhou, Z., Gallick, G. E., Jia, S.-F., Morales, J., Sood, A. K., Corey, S. J., & Kleinerman, E. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0058 · Cited by 55
“some translocation associated with Ewing’s sarcomas (1).”
BackgroundCurrent management of pediatric soft tissue sarcomas
Sangkhathat, S. (2015) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v4.i4.94 · Cited by 55
Ewing sarcoma: a chronicle of molecular pathogenesis
Kim, S. K., & Park, Y.-K. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.05.008 · Cited by 56
Zhang, P., Crow, J., Lella, D. J., Zhou, X. M., Samuel, G., Godwin, A. K., & Zeng, Y. (2018) · Lab on a Chip · doi:10.1039/c8lc01071d · Cited by 58
Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities
Anderson, J. L., Denny, C. T., Tap, W. D., & Federman, N. C. (2012) · Pediatric Research · doi:10.1038/pr.2012.54 · Cited by 55
“The most common EWS-ETS fusion, EWS-FLI1, is generated from the t(11;22)(q24;q12) reciprocal translocation that combines the N-terminal EWS activation domain and the C-terminal ETS DNA-binding domain of FLI1 (9) (Figure 1a).”
BackgroundInduction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation.
de Nigris, F., Mega, T., Berger, N., Barone, M. V., Santoro, M. M., Viglietto, G., Verde, P., & Fusco, A. (2001) · PubMed · Cited by 55
EWS/FLI1 Oncogene Activates Caspase 3 Transcription and Triggers Apoptosis In vivo
Sohn, E. J., Li, K., Reidy, K. T., Beers, L. F., Christensen, B. L., & Lee, S. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1993 · Cited by 62
“somal translocation t(11;22)(q24;q12), resulting in the fusion of EWS to FLI1 (2, 3).”
InfluentialCurrent insights into the role of Fli-1 in hematopoiesis and malignant transformation
Ben-David, Y., Gajendran, B., Sample, K. M., & Zacksenhaus, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04160-1 · Cited by 54
EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma
Shi, X., Zheng, Y., Jiang, L., Zhou, B. O., Yang, W., Li, L., Ding, L., Huang, M., Gery, S., Lin, D., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa901 · Cited by 59
Shulman, D. S., Whittle, S. B., Surdez, D., Bailey, K. M., de Álava, E., Yustein, J. T., Shlien, A., Hayashi, M., Bishop, A. J. R., Crompton, B. D., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00307-2 · Cited by 62
Self-citationApfelbaum, A. A., Wrenn, E. D., & Lawlor, E. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1044707 · Cited by 53
“EWS::FLI1 was the first identified fusion protein and occurs in ~85% of tumors (7, 11).”
BackgroundLi, H., Smolen, G. A., Beers, L. F., Li, X., Gerald, W. L., Wang, J., Haber, D. A., & Lee, S. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002353 · Cited by 59
“The EWS gene was first cloned from the Ewing’s sarcoma chromosomal breakpoint, where the translocation generates a fusion between EWS and an ETS-family transcription factor gene, FLI-1 [7].”
BackgroundProgrammed cell death ligand 1 (PD‐L1) expression is not a predominant feature in Ewing sarcomas
Spurny, C., Kailayangiri, S., Jamitzky, S., Altvater, B., Wardelmann, E., Dirksen, U., Hardes, J., Hartmann, W., & Rossig, C. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.26719 · Cited by 48
A Novel FUS/CHOP Chimera in Myxoid Liposarcoma
Panagopoulos, I., Mertens, F., Isaksson, M., & Mandahl, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4026 · Cited by 54
Prima, V., Gore, L., Caires, A., Boomer, T., Yoshinari, M., Imaizumi, M., Varella-Garcia, M., & Hunger, S. P. (2005) · Leukemia · doi:10.1038/sj.leu.2403684 · Cited by 54
O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma
Bachmaier, R., Aryee, D. N. T., Jug, G., Kauer, M. O., Kreppel, M., Lee, K. A. W., & Kovar, H. (2009) · Oncogene · doi:10.1038/onc.2008.484 · Cited by 57
“(Delattre et al., 1992).”
Self-citationEllis, J. A., Rothrock, R. J., Moise, G., McCormick, P. C., Tanji, K., Canoll, P., Kaiser, M. G., & McCormick, P. C. (2010) · Neurosurgical FOCUS · doi:10.3171/2010.10.focus10217 · Cited by 53
“6,16,88,98 The presence of an (11;22) (q24;q12) translocation is therefore the strongest diagnostic tool in identifying Ewing sarcoma/PNET.”
Methodvan der Ent, W., Jochemsen, A. G., Teunisse, A. F. A. S., Krens, G., Szuhai, K., Spaink, H. P., Hogendoorn, P. C. W., & Snaar-Jagalska, E. B. (2014) · The Journal of Pathology · doi:10.1002/path.4378 · Cited by 57
“The two most common gene fusions are EWSR1–FLI1 (85% of cases) and EWSR1–ERG (10% of cases) [3,4].”
BackgroundProtein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis
Luo, W., Xu, C., Ayello, J. S., Cruz, F. S. D., Rosenblum, J., Lessnick, S. L., & Cairo, M. S. (2017) · Oncogene · doi:10.1038/onc.2017.378 · Cited by 57
Jin, L. G., Majerus, J. A., Oliveira, A. M., Inwards, C. Y., Nascimento, A. G., Burgart, L. J., & Lloyd, R. V. (2003) · Diagnostic Molecular Pathology · doi:10.1097/00019606-200312000-00006 · Cited by 53
“Some primers and internal probes used were from earlier studies.(1,4,8,9) The primers for EWSex7/Fli-1ex9 were used for FS and EWSex7/Fli-1ex6 for PS.”
MethodTel-2 Is a Novel Transcriptional Repressor Related to the Ets Factor Tel/ETV-6
Gu, X., Shin, B., Akbarali, Y., Weiss, A., Boltax, J., Oettgen, P., & Libermann, T. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010070200 · Cited by 56
Shukla, N. N., Patel, J. A., Magnan, H., Zehir, A., You, D., Tang, J., Meng, F., Samoila, A., Slotkin, E. K., Ambati, S. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00028 · Cited by 52
Emerging therapies in Ewing sarcoma
Strauss, S. J., Berlanga, P., & McCabe, M. G. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001048 · Cited by 55
“Therefore, there remains a significant unmet to better tailor family of genes, most commonly EWSR1::FLI1 [1].”
BackgroundPromoter-Associated Long Noncoding RNAs Repress Transcription Through a RNA Binding Protein TLS
Kurokawa, R. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0332-6_12 · Cited by 57
Jacques, C., Lamoureux, F., Baud’huin, M., Calleja, L. R., Quillard, T., Amiaud, J., Tirode, F., Rédiní, F., Bradner, J. E., Heymann, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8214 · Cited by 56
“com/oncotarget fusion between the 5ʹ segment of the EWSR1 gene (Ewing sarcoma breakpoint region 1) on the chromosome 22 and the 3ʹ portion of Fli1 (Friend leukemia virus integration site 1), located on the chromosome 11 [7].”
Recent advances in targeted therapy for Ewing sarcoma
Pishas, K. I., & Lessnick, S. L. (2016) · F1000Research · doi:10.12688/f1000research.8631.1 · Cited by 52
Kedage, V., Selvaraj, N., Nicholas, T. R., Budka, J. A., Plotnik, J. P., Jerde, T. J., & Hollenhorst, P. C. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.001 · Cited by 56
“In contrast, the oncogenic product of an Ewing’s sarcoma translocation is a fusion protein consisting of an N-terminal domain of the RNA binding protein EWS fused to a C-terminal region of an ETS protein (Delattre et al., 1992; Patel et al., 2012).”
BackgroundAlaei-Mahabadi, B., Bhadury, J., Karlsson, J. W., Nilsson, J. A., & Larsson, E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606220113 · Cited by 58
“These may produce chimeric mRNAs encoding novel oncogenic proteins (4, 5) or, alternatively, fusion mRNAs that maintain their protein-coding sequence while being transcriptionally induced or repressed due to swapping of 5′ ends, including the promoter (6).”
BackgroundSatterfield, L., Shuck, R. L., Kurenbekova, L., Allen‐Rhoades, W. A., Edwards, D. P., Huang, S., Rajapakshe, K., Coarfa, C., Donehower, L. A., & Yustein, J. T. (2017) · International Journal of Cancer · doi:10.1002/ijc.30909 · Cited by 56
“Tumors often arise in the central axis and are identified by the presence of the oncogenic EWS-FLI1 fusion transcript.(1) Treatment consists of surgery and/or radiation therapy along with high dose cytotoxic systemic chemotherapy that has improved survival rates for patients with localized disease to approximately 70–…”
Cohen, J. N., Sabnis, A. J., Krings, G., Cho, S., Horvai, A., & Davis, J. L. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.03.020 · Cited by 52
Primary Ewing Sarcoma of the Brain
Kazmi, S. A. J., Perry, A., Pressey, J. G., Wellons, J. C., Hammers, Y. A., & Palmer, C. A. (2007) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3180375541 · Cited by 52
Makino, H., Toyoda, M., Matsumoto, K., Saito, H., Nishino, K., Fukawatase, Y., Machida, M., Akutsu, H., Uyama, T., Miyagawa, Y., et al. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.06.016 · Cited by 53
Zucman‐Rossi, J., Batzer, M. A., Stoneking, M., Delattre, O., & Thomas, G. D. (1997) · Human Genetics · doi:10.1007/s004390050372 · Cited by 65
“The EWS gene, located on chromosome 22q12, was originally identified as being rearranged by a recurrent t(11;22) translocation in the Ewing family of tumors (Delattre et al. 1992).”
BackgroundSelf-citationp53 mutations in human tumors with chimeric EWS/FLI/1 genes
Hamelin, R., Zucman‐Rossi, J., Melot, T., Delatre, O., & Thomas, G. D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910570308 · Cited by 53
Self-citationThe Possible Role of EWS-Fli1 in Evasion of Senescence in Ewing Family Tumors
Matsunobu, T., Tanaka, K., Nakamura, T., Nakatani, F., Sakimura, R., Hanada, M., Li, X., Okada, T., Oda, Y., Tsuneyoshi, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1972 · Cited by 53
“somes 11 and 22 is found in over 85% of EFTs (2), which results in the generation of the EWS-Fli1 chimeric gene (3).”
BackgroundProspects and challenges for the development of new therapies for Ewing sarcoma
Grohar, P. J., & Helman, L. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.10.004 · Cited by 51
“The most common fusion transcription involves EWSR1 and FLI1 and is derived from the t(11;22)(q24;q12) chromosomal translocation (Delattre et al., 1992; May et al., 1993).”
BackgroundInfluentialRNA-binding proteins as molecular links between cancer and neurodegeneration
Campos‐Melo, D., Droppelmann, C. A., Volkening, K., & Strong, M. J. (2014) · Biogerontology · doi:10.1007/s10522-014-9531-2 · Cited by 53
Grohar, P. J., Kim, S., Rivera, G. O. R., Sen, N., Haddock, S., Harlow, M. L., Maloney, N., Zhu, J., O’Neill, M. J., Jones, T. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.063 · Cited by 56
Hingorani, P., Janeway, K. A., Crompton, B. D., Kadoch, C., Mackall, C. L., Khan, J. I., Shern, J. F., Schiffman, J. D., Mirabello, L. J., Savage, S. A., et al. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.03.004 · Cited by 55
Horst, D. A., Gu, X., Bhasin, M., Yang, Q., Verzi, M. P., Lin, D., Joseph, M. G., Zhang, X., Chen, W., Li, Y.-P., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164541 · Cited by 51
Is There a Predisposition Gene for Ewing's Sarcoma?
Randall, R. L., Lessnick, S. L., Jones, K. B., Gouw, L. G., Cummings, J. E., Cannon‐Albright, L., & Schiffman, J. D. (2010) · Journal of Oncology · doi:10.1155/2010/397632 · Cited by 54
“[21] O.”
BackgroundInfluential3D tissue-engineered model of Ewing's sarcoma
Lamhamedi-Cherradi, S.-E., Santoro, M., Ramamoorthy, V., Menegaz, B. A., Bartholomeusz, G. A., Iles, L. R., Amin, H. M., Livingston, J. A., Mikos, A. G., & Ludwig, J. A. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.07.012 · Cited by 57
Ewing sarcoma family of tumors
West, D. C. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200007000-00008 · Cited by 61
Robinson, L., Panayiotakis, A., Papas, T. S., Kola, I., & Seth, A. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7170 · Cited by 55
Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway
Lagares‐Tena, L., García-Monclús, S., López‐Alemany, R., Almacellas‐Rabaiget, O., Huertas-Martínez, J., Sáinz‐Jaspeado, M., Mateo‐Lozano, S., Galindo, C. R., Rello‐Varona, S., Herrero‐Martín, D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10872 · Cited by 50
“ES tumors have a distinctive chromosomal translocation that gives rise to a fusion protein, most commonly EWS/FLI1 (85% of cases) [2, 3].”
BackgroundLiu, T., Xia, L., Yao, Y., Chen, Y., Fan, Y., Gajendran, B., Yang, J., Li, Y., Chen, J., Filmus, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1363-1 · Cited by 50
Wang, S., Hwang, E. E., Guha, R., O'Neill, A. F., Melong, N., Veinotte, C. J., Saur, A. C., Wuerthele, K., Shen, M., McKnight, C. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0375 · Cited by 55
“The resulting fusion protein, most commonly EWS/FLI, is believed to be the oncogenic driving event in this disease (3).”
HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction
Neckles, C., Boer, R. E., Aboreden, N. G., Cross, A. M., Walker, R. L., Kim, B., Kim, S. T., Schneekloth, J. S., & Caplen, N. J. (2019) · RNA · doi:10.1261/rna.072454.119 · Cited by 52
“Briefly, the pathology in ∼85% of EWS is caused by a translocation involving chromosomes 11 and 22, which results in a fusion between the 5′ end of the EWSR1 (Ewing sarcomabreakpoint region 1) and the 3′ end of the FLI1 (Friend leukemia virus integration site 1) genes (Delattre et al. 1992;May et al. 1993).”
Exosomes in Bone Sarcomas: Key Players in Metastasis
Chicón-Bosch, M., & Tirado, O. M. (2020) · Cells · doi:10.3390/cells9010241 · Cited by 47
Salicioni, A. M., Xi, M., Vanderveer, L., Balsara, B., Testa, J. R., Dunbrack, R. L., & Godwin, A. K. (2000) · Genomics · doi:10.1006/geno.2000.6315 · Cited by 50
SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas
Pascual‐Pasto, G., Castillo‐Ecija, H., Unceta, N., Aschero, R., Resa‐Pares, C., Gómez‐Caballero, A., Vilà-Ubach, M., Muñoz‐Aznar, O., Suñol, M., Burgueño, V., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.035 · Cited by 51
The Molecular Biology of Soft-Tissue Sarcomas and Current Trends in Therapy
Quesada, J., & Amato, R. (2012) · Sarcoma · doi:10.1155/2012/849456 · Cited by 50
“The translocated genes give origin to a chimeric fusion gene encoding an aberrant transcription factor which alters several cell signaling pathways affecting proliferation and apoptosis leading to invasiveness and metastasis [43].”
BackgroundChebib, I. A., & Jo, V. Y. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21685 · Cited by 49
“transcription factors, most frequently FLI1 (encoded on 11q24).(1,2) Other ETS-family fusion partners include ERG (21q22),(3) ETV1 (7p22),(4) E1AF,(5) and FEV (2q35-36),(6) and infrequent variant translocation involving FUS (in lieu of EWSR1) to ETS partners also is observed.”
BackgroundGoss, K. L., & Gordon, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.11416 · Cited by 54
“Ewing sarcoma tumors are defined by a recurrent chromosomal translocation between the EWSR1 gene and various ETS genes; the most common fusion, EWS-FLI1, is present in 85% of cases [2].”
BackgroundUpdate on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas
Loarer, F. L., Pissaloux, D., Coindre, J., Tirode, F., & Ranchère‐Vince, D. (2017) · Surgical pathology clinics · doi:10.1016/j.path.2017.04.002 · Cited by 49
Ernst, E. H., Nielsen, J., Ipsen, M. B., Villesen, P., & Lykke‐Hartmann, K. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00078 · Cited by 54
“, 1993), EWS (Delattre et al., 1992), and TAF15 (TAFII68, TAF2N, RBP56) (Crozat et al.”
EWSR1 fusions: Ewing sarcoma and beyond
Jo, V. Y. (2020) · Cancer Cytopathology · doi:10.1002/cncy.22239 · Cited by 49
“This translocation results in a fusion gene involving the Ewing sarcoma breakpoint region 1 gene (EWSR1) and the friend leukemia virus integration 1 gene (FLI1).(2,3) Since discovery of the EWSR1-FLI1 fusion in Ewing sarcoma, numerous studies have led to insights into the molecular mechanisms of tumorigenesis in Ewing…”
BackgroundVohra, M., Sharma, A. R., Prabhu, N. B., & Padmalatha, S. (2020) · Public Health Genomics · doi:10.1159/000510253 · Cited by 56
Chugh, R. K., Ballman, K. V., Helman, L. J., PATEL, S. R., Whelan, J., Widemann, B. C., Lu, Y., Hawkins, D. S., Mascarenhas, L., Glod, J. W., et al. (2020) · Cancer · doi:10.1002/cncr.33349 · Cited by 49
“C1 3 NIR at 200 mg qd D1-7 100 (93-100) 2 (1-2) None TMZ at 30 mg/m(2) qd D2-6”
InfluentialLu, D. Y., Ellegast, J. M., Ross, K. N., Malone, C. F., Lin, S., Mabe, N. W., Dharia, N. V., Meyer, A., Conway, A. S., Su, A. H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01059-8 · Cited by 57
Mezzelani, A., Tornielli, S., Minoletti, F., Pierotti, M. A., Sozzi, G., & Pilotti, S. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690734 · Cited by 49
“FISH on interphase nuclei was carried out in three using cosmid probes flanking the fusion gene (EWS/FL (Delattre et al, 1992; Zucman et al, 1992) and with a centrom probe for chromosome 8 (D8Z2) in order to determine the p ence of the t(11;22)(q24;12) translocation (Desmaze et al, 1 and trisomy 8…”
MethodPotentials for RNAi in sarcoma research and therapy: Ewing’s sarcoma as a model
Kovar, H., Ban, J., & Pospı́šilová, Š. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(03)00041-5 · Cited by 49
Self-citationInduction of a secreted protein by the myxoid liposarcoma oncogene
Kuroda, M., Wang, X.-Z., Sok, J. C., Yin, Y., Chung, P. W. M., Giannotti, J. W., Jacobs, K. A., Fitz, L. J., Murtha-Riel, P., Turner, K. J., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5025 · Cited by 51
Liang, H., Olejniczak, E. T., Mao, X., Nettesheim, D. G., Yu, L., Thompson, C. B., & Fesik, S. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11655 · Cited by 49
Dupriez, V. J., Darville, M. I., Antoine, I. V., Gegonne, A., Ghysdael, J., & Rousseau, G. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8224 · Cited by 49
Inactivation of EWS reduces PGC-1α protein stability and mitochondrial homeostasis
Park, J. H., Kang, H., Lee, Y. K., Kang, H., Kim, J., Chung, J. H., Chang, J. S., McPherron, A. C., & Lee, S. B. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504391112 · Cited by 49
“E sarcoma breakpoint region 1 (EWSR1, herein termed EWS) was first identified from the Ewing sarcoma chromosomal breakpoint t(11, 22)(q24;q12) region as a translocationgenerated fusion gene between EWS and FLI1 (Friend leukemia integration 1) (1), an ETS-family of transcription factor.”
BackgroundPromiscuous genes involved in recurrent chromosomal translocations in soft tissue tumours
Antonescu, C. R., & Cin, P. D. (2013) · Pathology · doi:10.1097/pat.0000000000000049 · Cited by 48
“The Ewing sarcoma breakpoint region 1 (EWSR1; also known as EWS) gene rearrangements were first identified in Ewing sarcoma, being fused to members of the ETS transcription factors family.(16) However, EWSR1 fusions have been now”
BackgroundTakigami, I., Ohno, T., Kitade, Y., Hara, A., Nagano, A., Kawai, G., Saitou, M., Matsuhashi, A., Yamada, K., & Shimizu, K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25564 · Cited by 50
Drug-mediated inhibition of Fli-1 for the treatment of leukemia
Yj, L., Zhao, X., Vecchiarelli-Federico, L. M., Li, Y., Datti, A., Cheng, Y., & Ben‐David, Y. (2012) · Blood Cancer Journal · doi:10.1038/bcj.2011.52 · Cited by 49
Navarro, D., Agrá, N., Pestaña, Á., Alonso, J., & González‐Sancho, J. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp317 · Cited by 56
Shukla, N. N., Somwar, R., Smith, R. S., Ambati, S., Munoz, S., Merchant, M. S., D’Arcy, P., Wang, X., Kobos, R., Antczak, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1040 · Cited by 52
“Ewing sarcoma (EWS) is the second most common bone malignancy in children, with a peak incidence in adolescence and is characterized by specific translocations leading to the fusion of EWSR1 to a gene of the ETS family of transcription factors.(1,2) Although localized disease is curable with highly intensive chemother…”
BackgroundClonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding
Veninga, A., Simone, I. D., Heemskerk, J. W. M., Cate, H. T., & van der Meijden, P. E. J. (2020) · Haematologica · doi:10.3324/haematol.2019.235994 · Cited by 49
“In the case of somatic mutations, FLI1 can become fusion partner with the transcriptional repressing gene EWSR1, a condition known as Ewing sarcoma.(86) The effect on platelets is unclear.”
BackgroundVEGFR2 as a target for CAR T cell therapy of Ewing sarcoma
Englisch, A., Altvater, B., Kailayangiri, S., Hartmann, W., & Rössig, C. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28313 · Cited by 49
Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma
Ohmura, S., Marchetto, A., Orth, M. F., Li, J., Jabar, S., Ranft, A., Vinca, E., Ceranski, A. K., Carreño-Gonzalez, M. J., Romero‐Pérez, L., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01393-9 · Cited by 54
“It is characterized by chromosomal translocations fusing members of the FET gene family (EWSR1 or FUS) to variable ETS transcription factors, most commonly FLI1 (85% of cases) (2,3).”
BackgroundTirado, Ò. M., MacCarthy, C. M., Fatima, N., Villar, J., Mateo‐Lozano, S., & Notario, A. V. (2009) · International Journal of Cancer · doi:10.1002/ijc.24754 · Cited by 49
“These hybrid EWS/FLI1 genes are heterogeneous with regard to the location of the translocation junction, resulting in different breakpoints(2) but, regardless of the fusion type, all EWS/FLI1 proteins act as aberrant transcription factors that are responsible for the malignant properties of ESFT.(3) Multimodal therape…”
BackgroundInfluentialNishio, J., Iwasaki, H., Ishiguro, M., Ohjimi, Y., Fujita, C., Yanai, F., Nibu, K., Mitsudome, A., Kaneko, Y., & Kikuchi, M. (2002) · Laboratory Investigation · doi:10.1097/01.lab.0000028059.92642.03 · Cited by 48
“The forward primer for EWS exon 7 was 5'-TCCTACAGCCAAGCTCCAAGTC-3', primer 22.3 (Delattre et al, 1992).”
BackgroundInfluentialInterphase Cytogenetic Analysis of Solid Tumors by Non-Isotopic DNA in situ Hybridization
Alers, J. C., & van Dekken, H. (1996) · Progress in Histochemistry and Cytochemistry · doi:10.1016/s0079-6336(96)80017-9 · Cited by 50
A review of the cytogenetics of 58 pediatric brain tumors
Roberts, P., Chumas, P., Picton, S. V., Bridges, L., Livingstone, J., & Sheridan, E. G. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00483-6 · Cited by 48
Arvand, A., Welford, S. M., Teitell, M. A., & Denny, C. T. (2001) · PubMed · Cited by 60
Perani, M., Antonson, P., Hamoudi, R., Ingram, C. J. E., Cooper, C. S., Garrett, M. D., & Goodwin, G. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502963200 · Cited by 53
Felsch, J. S., Lane, W. S., & Peralta, E. G. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80214-0 · Cited by 51
The ETS Family of Transcriptional Regulators
Ghysdael, J., & Boureux, A. (1997) · Oncogenes as Transcriptional Regulators · doi:10.1007/978-3-0348-8889-9_2 · Cited by 48
Evolving techniques for gene fusion detection in soft tissue tumours
Mertens, F., & Tayebwa, J. (2013) · Histopathology · doi:10.1111/his.12272 · Cited by 50
“As had been the case for leukaemias and lymphomas, recurrent balanced rearrangements attracted particular attention, and in 1992 the first sarcoma-associated gene fusion – the EWSR1–FLI1 chimera resulting from t(11;22)(q24;q12) in Ewing sarcoma – was discovered.(49) During the following 20 years, new gene fusions were…”
BackgroundFidaleo, M., Svetoni, F., Volpe, E., Miñana, B., Caporossi, D., & Paronetto, M. P. (2015) · Oncotarget · doi:10.18632/oncotarget.5033 · Cited by 47
Metadata
- Authors
- Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., Aurias, A., & Thomas, G.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6391
- Pages
- 162-165
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2069351898
- Cited by
- 1,907
- References
- 30
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 69 · 2023: 64 · 2022: 78 · 2021: 83 · 2020: 80 · 2019: 69 · 2018: 54 · 2017: 57 · 2016: 71 · 2015: 62 · 2014: 61 · 2013: 63 · 2012: 45
- FWCI
- 60.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Ewing sarcoma, primitive neuroectodermal tumor, 22)(q24, EWSR1, gene fusion, chromosomal translocation, RNA-binding domain
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 22, Cloning, Molecular, Gene Frequency, Humans, Molecular Sequence Data, Nucleic Acid Hybridization, Sarcoma, Ewing, Sequence Homology, Nucleic Acid, Transcription, Genetic, Translocation, Genetic, Restriction Mapping, DNA Probes, Polymerase Chain Reaction, Open Reading Frames, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.